NYSE:GMED Globus Medical Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Globus Medical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $57.72 +1.58 (+2.81%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$55.86▼$57.9350-Day Range$53.08▼$70.1452-Week Range$52.60▼$84.23Volume469,722 shsAverage Volume724,298 shsMarket Capitalization$5.87 billionP/E Ratio42.44Dividend YieldN/APrice Target$83.18 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Globus Medical Stock Forecast (MarketRank)Analyst RatingModerate Buy2.90 Rating ScoreUpside/Downside44.1% Upside$83.18 Price TargetShort InterestBearish6.18% of Float Sold ShortDividend StrengthN/ASustainability-0.93Upright™ Environmental ScoreNews Sentiment1.00Based on 2 Articles This WeekInsider TradingSelling Shares$2.65 M Sold Last QuarterProj. Earnings Growth14.29%From $2.10 to $2.40 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.75 out of 5 starsMedical Sector51st out of 1,428 stocksSurgical & Medical Instruments Industry8th out of 137 stocks 3.5 Analyst's Opinion Consensus RatingGlobus Medical has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $83.18, Globus Medical has a forecasted upside of 44.1% from its current price of $57.72.Amount of Analyst CoverageGlobus Medical has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.18% of the float of Globus Medical has been sold short.Short Interest Ratio / Days to CoverGlobus Medical has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Globus Medical has recently increased by 2.66%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldGlobus Medical does not currently pay a dividend.Dividend GrowthGlobus Medical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGlobus Medical has received a 57.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Neurostimulators", "Synthetic bone grafts", "Artificial joints", and "Robotic surgery systems" products. See details.Environmental SustainabilityThe Environmental Impact score for Globus Medical is -0.93. Previous Next 2.8 News and Social Media Coverage News SentimentGlobus Medical has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Globus Medical this week, compared to 2 articles on an average week.Search Interest4 people have searched for GMED on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Globus Medical to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Globus Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,646,895.00 in company stock.Percentage Held by Insiders16.50% of the stock of Globus Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.19% of the stock of Globus Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Globus Medical are expected to grow by 14.29% in the coming year, from $2.10 to $2.40 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Globus Medical is 42.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 64.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Globus Medical is 42.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 63.45.Price to Earnings Growth RatioGlobus Medical has a PEG Ratio of 2.45. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGlobus Medical has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globus Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address About Globus Medical (NYSE:GMED)Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.Read More GMED Stock News HeadlinesJune 27, 2022 | finance.yahoo.comWhy Globus Medical (GMED) is a Top Growth Stock for the Long-TermJune 18, 2022 | morningstar.comGlobus Medical Inc Class A - Stock Quote GMEDJune 10, 2022 | msn.comGlobus Medical's Return On Invested Capital InsightsJune 9, 2022 | finance.yahoo.comWhy Is Globus Medical (GMED) Up 1.7% Since Last Earnings Report?June 7, 2022 | finance.yahoo.comHere's Why Investors Should Retain Globus Medical (GMED) NowJune 6, 2022 | finance.yahoo.comThe total return for Globus Medical (NYSE:GMED) investors has risen faster than earnings growth over the last five yearsMay 20, 2022 | nasdaq.comFirst Week of July 15th Options Trading For Globus Medical (GMED)May 18, 2022 | finance.yahoo.comGlobus Medical Announces First Surgeries Using Excelsius3D™May 11, 2022 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Globus MedicalMay 11, 2022 | fool.comGlobus Medical (GMED) Q1 2022 Earnings Call TranscriptMay 10, 2022 | seekingalpha.comGlobus Medical, Inc. (GMED) CEO Dan Scavilla on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | finance.yahoo.comGlobus Medical (GMED) Misses Q1 Earnings and Revenue EstimatesMay 10, 2022 | finance.yahoo.comGlobus Medical Reports First Quarter 2022 ResultsMay 9, 2022 | seekingalpha.comGlobus Medical Q1 2022 Earnings PreviewMay 6, 2022 | finance.yahoo.comAre Investors Undervaluing Globus Medical, Inc. (NYSE:GMED) By 43%?April 22, 2022 | nasdaq.comGMED Crosses Below Key Moving Average LevelApril 22, 2022 | msn.comGlobus Medical (GMED) Stock Fell on Preliminary Q1 Sales ResultsApril 22, 2022 | finance.yahoo.comGlobus Medical Issues Softer Outlook For Q1, CEO ResignsApril 22, 2022 | finance.yahoo.comMedical device manufacturer Globus Medical transitions to new CEOApril 22, 2022 | finance.yahoo.comWhy Globus Medical Stock Is Sinking TodayApril 21, 2022 | seekingalpha.comGlobus Medical drops 14% on prelim Q1 sales figure below consensus, names new CEOApril 7, 2022 | finance.yahoo.com3 Healthcare Stocks That Could Help Set You Up for LifeMarch 28, 2022 | markets.businessinsider.comWhere Globus Medical Stands With AnalystsMarch 27, 2022 | finance.yahoo.comBe Wary Of Globus Medical (NYSE:GMED) And Its Returns On CapitalMarch 4, 2022 | seekingalpha.comGlobus Medical expands buyback program by additional $200MSee More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:GMED CUSIP37957720 CIK1237831 Webwww.globusmedical.com Phone(610) 930-1800Fax610-930-2042Employees2,400Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/02/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$83.18 High Stock Price Forecast$100.00 Low Stock Price Forecast$70.00 Forecasted Upside/Downside+44.1%Consensus RatingModerate Buy Rating Score (0-4)2.9 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$1.36 Trailing P/E Ratio42.44 Forward P/E Ratio27.49 P/E Growth2.45Net Income$149.19 million Net Margins14.77% Pretax Margin17.90% Return on Equity11.95% Return on Assets10.69% Debt Debt-to-Equity RatioN/A Current Ratio6.48 Quick Ratio4.68 Sales & Book Value Annual Sales$958.10 million Price / Sales6.13 Cash Flow$2.79 per share Price / Cash Flow20.68 Book Value$17.15 per share Price / Book3.37Miscellaneous Outstanding Shares101,751,000Free Float84,962,000Market Cap$5.87 billion OptionableOptionable Beta1.11 Globus Medical Frequently Asked Questions Should I buy or sell Globus Medical stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Globus Medical in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Globus Medical stock. View analyst ratings for Globus Medical or view top-rated stocks. What is Globus Medical's stock price forecast for 2022? 10 Wall Street research analysts have issued 12 month price objectives for Globus Medical's shares. Their GMED stock forecasts range from $70.00 to $100.00. On average, they anticipate Globus Medical's share price to reach $83.18 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts' price targets for Globus Medical or view top-rated stocks among Wall Street analysts. How has Globus Medical's stock performed in 2022? Globus Medical's stock was trading at $72.20 at the beginning of the year. Since then, GMED shares have decreased by 20.1% and is now trading at $57.72. View the best growth stocks for 2022 here. When is Globus Medical's next earnings date? Globus Medical is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Globus Medical. How were Globus Medical's earnings last quarter? Globus Medical, Inc. (NYSE:GMED) issued its quarterly earnings results on Tuesday, May, 10th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by $0.04. The medical device company had revenue of $230.55 million for the quarter, compared to analyst estimates of $232.88 million. Globus Medical had a trailing twelve-month return on equity of 11.95% and a net margin of 14.77%. The firm's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 earnings per share. View Globus Medical's earnings history. What guidance has Globus Medical issued on next quarter's earnings? Globus Medical issued an update on its FY 2022 earnings guidance on Tuesday, June, 7th. The company provided earnings per share (EPS) guidance of $2.10-$2.10 for the period, compared to the consensus estimate of $2.10. The company issued revenue guidance of $1.02 billion-$1.02 billion, compared to the consensus revenue estimate of $1.03 billion. Who are Globus Medical's key executives? Globus Medical's management team includes the following people: Mr. David C. Paul, Co-Founder & Exec. Chairman (Age 55, Pay $23.57k)Mr. Daniel T. Scavilla, Pres, CEO & Director (Age 57, Pay $965.17k) (LinkedIn Profile)Mr. Keith W. Pfeil, Sr. VP & CFO (Age 43, Pay $623.41k) (LinkedIn Profile)Ms. Kelly G. Huller Esq., Sr. VP, Gen. Counsel & Sec. (Age 50, Pay $543.02k)Mr. Brian J. Kearns, Sr. VP of Bus. Devel. & Investor Relations (Age 55)Mr. A. Brett Murphy, Exec. VP of International Sales (Age 57)Mr. Steven M. Payne, VP & Controller (Age 51)Mr. Mike Reeder, Exec. OfficerMr. Richard Holifield, Exec. OfficerMr. John Dowling, Exec. Officer What is David Demski's approval rating as Globus Medical's CEO? 47 employees have rated Globus Medical CEO David Demski on Glassdoor.com. David Demski has an approval rating of 61% among Globus Medical's employees. This puts David Demski in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Globus Medical's key competitors? Some companies that are related to Globus Medical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), Baxter International (BAX), ResMed (RMD), DexCom (DXCM), IDEXX Laboratories (IDXX), STERIS (STE), Hologic (HOLX), Insulet (PODD) and Teleflex (TFX). View all of GMED's competitors. What other stocks do shareholders of Globus Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Globus Medical investors own include NVIDIA (NVDA), Shopify (SHOP), CrowdStrike (CRWD), Okta (OKTA), Trade Desk (TTD), Square (SQ), Tesla (TSLA), Teladoc Health (TDOC), Zoom Video Communications (ZM) and Mastercard (MA). What is Globus Medical's stock symbol? Globus Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "GMED." How do I buy shares of Globus Medical? Shares of GMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Globus Medical's stock price today? One share of GMED stock can currently be purchased for approximately $57.72. How much money does Globus Medical make? Globus Medical (NYSE:GMED) has a market capitalization of $5.87 billion and generates $958.10 million in revenue each year. The medical device company earns $149.19 million in net income (profit) each year or $1.36 on an earnings per share basis. How many employees does Globus Medical have? Globus Medical employs 2,400 workers across the globe. How can I contact Globus Medical? Globus Medical's mailing address is 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA, 19403. The official website for Globus Medical is www.globusmedical.com. The medical device company can be reached via phone at (610) 930-1800, via email at investors@globusmedical.com, or via fax at 610-930-2042. This page (NYSE:GMED) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
